Cancer Patients Join Oncologist Who Releases Results of COVID-19 Vaccine/Cancer Study

On the heels of his study, Dr. James Berenson —– an oncologist specializing in multiple…

read more

IMBCR & Emory University’s Big Discovery!!!

Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response…

read more

James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center

New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative…

read more

Dedication of “Determination”

The Institute for Myeloma & Bone Cancer Research (IMBCR) is pleased to announce the dedication…

read more

Understanding Myeloma News About Secondary Cancers and Clotting

Dr. James Berenson helps patients understand new FDA recommendations regarding the use of lenalidomide (Revlimid)…

read more

Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting

Oncotherapeutics, an oncology specific Contract Research Organization (CRO) specializing in the oversight and management of…

read more

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

Leuk Res. 2011 Mar;35(3):373-9. doi: 10.1016/j.leukres.2010.06.026. Epub 2010 Jul 21. Sanchez E, Shen J, Steinberg…

read more

Kyphon® Balloon Kyphoplasty Found Beneficial for Treating Spinal Fractures in Cancer Patients

The results of this landmark study should be welcomed news to cancer patients across the…

read more

Counterpoints: To Transplant or Not To Transplant

More Is Not Better Claudia Andreu-Vieyra, Ph.D and James Berenson, M.D. Multiple myeloma (MM) is…

read more

Multiple Myeloma: ‘Old Rules’ No Longer Apply

Original Article Writen by: Robert Carlson – Oncology Times NEW YORK—Treatment regimens for relapsed/refractory multiple…

read more